Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial

C Chee Khoon Lee (Department of Medical Oncology, Cancer Care Centre, St. George Hospital, Kogarah, NSW, Australia) A Apriliana E. R. Kartikasari N Nirashaa T. Bound K Katherine E. Francis K Kristy Shield-Artin J Justin Bedo K Ksenija Nesic K Katrina Diamante R Rachel L. O’Connell M Mutsa Madondo M Momodou Cox C Claire Davies C Cyril Deceneux G Georgia Goodchild A Andrew Jarratt E Emily Cassar H Hina Amer U U. G. Imalki U. Kariyawasam Y Yeh Chen Lee J Janine Lombard S Sally Baron-Hay Y Yoland Antill C Catherine Shannon S Sudarshan Selva-Nayagam P Philip Beale D Danka Zebic S Sandy Simon A Anneliese Linaker M Michael A. Quinn A Anthony T. Papenfuss M Matthew J. Wakefield C Cassandra J. Vandenberg M Michael Friedlander C Clare L. Scott M Magdalena Plebanski

Abstract

Abstract SOLACE2 (ACTRN12618000686202) investigates whether 12-weeks of olaparib, or cyclophosphamide-olaparib priming, improves subsequent durvalumab-olaparib progression-free survival (PFS), and is superior to olaparib monotherapy without any priming, in platinum-sensitive recurrent ovarian cancer (n = 114). We also evaluate the utility of CUP-CC assay, an immune signature of C-C chemokine receptor type 4 up-regulation, chemokines, and cytokines. Priming with olaparib, or cyclophosphamide-olaparib, followed by durvalumab-olaparib, are both associated with longer PFS compared to olaparib monotherapy, but do not reach the pre-specified primary endpoint of 36-week trial threshold (PFS36). PFS36 rates are 47.4% (95% CI, 31.0-62.1; olaparib priming then olaparib-durvalumab), 48.7% (32.5-63.2; olaparib-cyclophosphamide then olaparib-durvalumab) and 35.1% (20.4-50.3; olaparib monotherapy). PFS is significantly longer for the homologous recombination deficient (N = 71) as compared to the proficient (HRP) (N = 29) subgroups (Hazard Ratio (HR) 0.55, 0.35-0.87). CUP-CC+ subgroup (N = 58) has a significantly longer PFS (HR 0.31, 0.19-0.49) than CUP-CC- (N = 46). Future studies should investigate whether CUP-CC has the potential to personalize poly (ADP-ribose) polymerase inhibitor therapies for patients who are BRCA wild-type, including HRP patients.

Article Details

Volume / Issue Vol. 16, Issue 1
Published November 05, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (35)

C

Chee Khoon Lee

Department of Medical Oncology, Cancer Care Centre, St. George Hospital, Kogarah, NSW, Australia

A

Apriliana E. R. Kartikasari

N

Nirashaa T. Bound

K

Katherine E. Francis

K

Kristy Shield-Artin

J

Justin Bedo

K

Ksenija Nesic

K

Katrina Diamante

R

Rachel L. O’Connell

M

Mutsa Madondo

M

Momodou Cox

C

Claire Davies

C

Cyril Deceneux

G

Georgia Goodchild

A

Andrew Jarratt

E

Emily Cassar

H

Hina Amer

U

U. G. Imalki U. Kariyawasam

Y

Yeh Chen Lee

J

Janine Lombard

S

Sally Baron-Hay

Y

Yoland Antill

C

Catherine Shannon

S

Sudarshan Selva-Nayagam

P

Philip Beale

D

Danka Zebic

S

Sandy Simon

A

Anneliese Linaker

M

Michael A. Quinn

A

Anthony T. Papenfuss

M

Matthew J. Wakefield

C

Cassandra J. Vandenberg

M

Michael Friedlander

C

Clare L. Scott

M

Magdalena Plebanski